Alnylam Pharmaceuticals Inc. has announced that its RNA interference therapeutic, OXLUMO® (lumasiran), has received funding and regulatory approval in Canada for the treatment of Primary Hyperoxaluria Type 1 (PH1) in both pediatric and adult patients. This approval comes as part of the National Strategy for Drugs for Rare Diseases and is supported by both public and private funding plans across Canada. The funding decision is a significant advancement for patients suffering from this ultra-rare genetic disorder, offering a new treatment option that has shown promising results in clinical studies. The ILLUMINATE clinical trials demonstrated significant reductions in urinary and plasma oxalate levels, which are critical in managing the disease's progression. The grant and approval are exclusive to Alnylam Pharmaceuticals Inc., highlighting their efforts in addressing rare diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.